Effects of monoglycerides on P-glycoprotein: Modulation of the activity and expression in Caco-2 cell monolayers

Molecular Pharmaceutics

Volumn 5, Issue 5, 2008, Pages 863-875

  Barta, Cheri A ^a   Sachs Barrable, Kristina ^a   Feng, Florina ^a   Wasan, Kishor M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

1 monoolein; 1 monostearin; Bifunctional transport; Caco 2; DPH; Lipid excipients; Monoglycerides; P gp; Rh123; TMA DPH; Verapamil

Indexed keywords

1 MONOOLEIN; 1 MONOSTEARIN; GLYCEROL DERIVATIVE; GLYCOPROTEIN P; MONOACYLGLYCEROL; RHODAMINE 123; UNCLASSIFIED DRUG;

ANISOTROPY; ARTICLE; CANCER CELL CULTURE; CELL MEMBRANE FLUIDITY; CELL MEMBRANE PERMEABILITY; CELL NUCLEUS MEMBRANE; CELL STRAIN CACO 2; COLON ADENOCARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INCUBATION TIME; MITOCHONDRIAL RESPIRATION; MONOLAYER CULTURE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TRANSPORT;

ADENOCARCINOMA; CACO-2 CELLS; CELL LINE, TUMOR; CELL MEMBRANE; COLONIC NEOPLASMS; GLYCERIDES; HUMANS; MONOGLYCERIDES; P-GLYCOPROTEIN; RHODAMINE 123;

EID: 56049094592     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp800050q     Document Type: Article

References (57)

1. Yang, S.; Gursoy, R. N.; Lambert, G.; Benita, S. Enhanced Oral Absoption of Paclitazel in a Novel Self-Microemulsifying Drug Delivery System with or without Comcomitant Use of P-glycoprotein Inhibitors. Pharm. Res. 2004, 21, 261-270.
2. Gursoy, R. N.; Benita, S. Self-emulsifying Drug Delivery Systems SEDDS) for Improved Oral Delivery of Lipophilic Drugs. Biomed. Pharmacother. 2004, 58, 173-182.
3. Seeballuck, F.; Ashford, M. B.; O'Driscoll, C. M. The Effects of Pluronic® Block Copolymers and Cremophor® EL on Intestinal Lipoprotein Processing and the Potential link with P-glycoprotein in Caco-2 Cells. Pharm. Res. 2003, 20, 1085-1092.
4. Constantinides, P. P.; Wasan, K. M. Lipid Formulation Strategies for Enhancing Intestinal Transport and Absorption of P-glycoprotein (P-gp) Substrate Drugs: In Vitro/In Vivo Case Studies. J. Pharm. Sci. 2007, 96, 235-248.
5. Porter, C. J. H.; Travaskis, N. L.; Charman, W. N. Lipids and Lipid-Based Formulations: Optimizing the Oral Delivery of Lipophilic Drugs. Nature 2007, 6, 231-248.
6. Fromm, M. F. Importance of P-glycoprotein at Blood-tissue Barriers. Trends Pharmacol. Sci. 2004, 25, 423-429.
7. Gottesman, M. W.; Fojo, T.; Bates, S. E. Multidrug Resistance in Cancer: Role of ATP-dependent Transporters. Nature 2002, 2, 48-58.
8. Leslie, E. M.; Deeley, R. G.; Cole, S. P. C. Multidrug Resistance Proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in Tissue Defense. Toxicol. Appl. Pharmacol. 2005, 204, 216-237.
9. Higgins, C. F. Multiple Molecular Mechanisms for Multidrug Resistance Transporters. Nature 2007, 446, 749-757.
10. Woodcock, D. M.; Linsenmeyer, M. E.; Chojnowski, G.; Kriegler, A. B.; Nink, V.; Webster, L. K. Reversal of Multidrug Resistance by Surfactants. Br. J. Cancer 1992, 66, 62-68.
11. Nerurkar, M. M.; Burton, P. S.; Borchardt, R. T. The Use of Surfactants to Enhance the Permeability of Peptides Through Caco-2 Cells by Inhibition of an Apically Polarized Efflux System. Pharm. Res. 1996, 13, 528-534.
12. Batrakova, E. V.; Han, H. Y.; Alakhov, V. Y.; Miller, D. W.; Kabanov, A. V. Effects of Pluronic Block Copolymers on Drug Absorption in Caco-2 Cell Monolayers. Pharm. Res. 1998, 15, 850-855.
13. Seeballuck, F.; Lawless, E.; Ashford, M. B.; O'Driscoll, C. M. Stimulation of Triglyceride-rich Lipoprotein Secretion by Polysorbate 80: In Vitro and In Vivo Correlation using Caco-2 Cells and a Cannulated Rat Intestinal Lymphatic Model. Pharm. Res. 2004, 21, 2320-2326.
14. Yu, L.; Bridgers, A.; Polli, J.; Vickers, A.; Long, S.; Roy, A.; Winnike, R.; Coffin, M. Viatmin E-TPGS Increased Absorption Flux of an HIV Protease Inhibitor by Enhancing Its Solubility and Permeability. Pharm. Res. 1999, 16, 1812-1817.
15. Sachs-Barrable, K.; Thamboo, A.; Lee, S. D.; Wasan, K. M. Lipid Excipients Peceol and Gelucire 44/14 Decrease P-glycoprotein Mediated Efflux of Rhodamine 123 Partially due to Modifying P-glycoprotein Protein Expression within Caco-2 Cells. J. Pharm. Pharm. Sci. 2007, 10, 319-331.
16. Risovic, V.; Sachs-Barrable, K.; Boyd, M.; Wasan, K. M. Potential Mechanims by Which Peceol® Increases the Gastrointestinal Absorption of Amphotericin B. Drug Dev. Ind. Pharm. 2004, 30, 767-774.
17. Konishi, T.; Satsu, H.; Hatsugai, Y.; Aizawa, K.; Inakuma, T.; Nagata, S.; Sakuda, S.-H.; Nagasawa, H.; Shimizu, M. Inhibitory Effect of a Bitter Melon Extract on the P-glycoprotein Activity in Intestinal Caco-2 Cells. Br. J. Pharmacol. 2004, 143, 379-387.
18. Konishi, T.; Satsu, H.; Hatsugai, Y.; Aizawa, K.; Inakuma, T.; Nagata, S.; Sakuda, S.-H.; Nagasawa, H.; Shimizu, M. A Bitter Melon Extract Inhibits the P-glycoprotein Activity in Intestinal Caco-2 Cells: Monoglyceride as an Active Compound. BioFactors 2004, 22, 71-74.
19. Englund, G.; Rorsman, F.; Ronnblom, A.; Karlbom, U.; Lazorova, L.; Grasjo, J.; Kindmark, A.; Artursson, P. Regional Levels of Drug Transporters Along the Human Intestinal Tract: Co-expression of ABC and SLC Transporters and Comparison with Caco-2 Cells. Eur. J. Pharm. Sci. 2006, 29, 269-277.
20. Meunier, V.; Bourrie, M.; Berger, Y.; Fabre, G. The Human Intestinal Epithelial Cell Line Caco-2; Pharmacological and Pharmacokinetic Applications. Cell Biol. Toxicol. 1995, 11, 187-194.
21. Hubatsh, I.; Ragnarsson, E. G. E.; Artursson, P. Nat. Protoc. 2007, 2, 2111-2119.
22. Wu, S. J.; Robinson, J. R. Transcellular and Lipophilic Complex-Enhanced Intestinal Absorption of Human Growth Hormone. Pharm. Res. 1999, 16, 1266-1272.
23. D'Souza, V. M.; Shertzer, H. G.; Menon, A. G.; Pauletti, G. M. High Glucose Concentration in Isotonic Media Alters Caco-2 Cell Permeability. AAPS PharmSci 2003, 5, 1-9.
24. Czubryt, M. P.; Ramjiawan, B.; Pierce, G. N. The Nuclear Membrane Integrity Assay. Mol. Cell. Biochem. 1997, 172, 97-102.
25. Vanchon, J. F.; Beaulieu, P. Transient Mosaic Patterns of Morphological and Functional Differentiation in the Caco-2 Cell Line. Gastroenterology 1992, 103, 414-423.
26. Garcia-Casal, M. N.; Leets, I.; Layrisse, M. Beta-carotene and Inhibitors of Iron Absorption Modify Iron Uptake by Caco-2 Cells. J. Nutr. 2000, 130, 5-9.
27. Ng, A. W. K.; Lukic, T.; Pritchard, H. P.; Wasan, K. M. Development of Novel Water-soluble Phytostanol Analogs: Disodium Ascorbyl Phytostanyl Phosphates FM-VP4: Preclinical Pharmacology, Pharmacokinetics and Toxicology. Cardiovasc. Drug Rev. 2003, 21, 151.
28. Yazdanian, M.; Glynn, S. L.; Wright, J. L.; Hawi, A. Correlating Partitioning and Caco-2 Cell Permeability of Structurally Diverse Small Molecular Weight Compounds. Pharm. Res. 1998, 15, 1490.
29. Okhee, H.; Failla, M. L.; Hill, D.; Morris, E. R.; Smith, J. C. Inositol Phosphates Inhibit Uptake and Transport of Iron and Zinc by a Human Intestinal Cell Line. J. Nutr. 1994, 124, 580-587.
30. Makhey, V. D.; Guo, A.; Norris, D. A.; Hu, P.; Yan, J.; Sinko, P. J. Characterization of the Regional Intestinal Kinetics of Drug Efflux in Rat and Human Intestine and in Caco-2 Cells. Pharm. Res. 1998, 15, 1160-1167.
31. Park, J. H. Y.; Kim, E. J.; Jin, H.; Jun. J.-G. Isolation and Identification of Oleamide as a Growth Inhibitory Compound from the Medium Conditioned by Colon Cancer Cells Treated with Conjugated Linoleic Acid. Bull. Korean Chem. Soc. 2002, 23, 1373-1374.
32. Vellonen, K.-S.; Honkakoski, P.; Urtti, A. Substrates and Inhibitors of Efflux Proteins Interfere with the MTT Assay in Cells and may lead to Underestimation of Drug Toxicity. Eur. J. Pharm. Sci. 2004, 23, 181-188.
33. Svensson, A.; Neves, C.; Cabane, B. Hydration of an Amphiphilic Excipient, Gelucire® 44/14. Int. J. Pharm. 2004, 281, 107-118.
34. Pétriz, J.; García-López, J. Flow Cytometric Analysis of P-glycoprotein Function using Rhodamine 123. Leukemia 1997, 11, 1124-1130.
35. Ludescher, C.; Thaler, J.; Drach, D.; Drach, J.; Spitaler, M.; Gattringer, C.; Huber, H.; Hofmann, J. Detection of Activity of P-glycoprotein in Human Tumour Samples using Rhodamine 123. Br. J. Haematol. 1992, 82, 161-168.
36. Bellamy, W. T. P-glycoproteins and Multidrug Resistance. Annu. Rev. Pharmacol. Toxicol. 1996, 36, 161-183.
37. Hugger, E. D.; Novak, B. L.; Burton, R. S.; Audus, K. L.; Borchardt, R. T. Effects of Poly(ethylene glycol) on Efflux Transporter Activity in Caco-2 Cell Monolayers. J. Pharm. Sci. 2002, 91, 1991-2002.
38. Hugger, E. D.; Audus, K. L.; Borchardt, R. T. A Comparison of Commonly Used Polyethoxylated Pharmaceutical Excipients on Their Ability to Inhibit P-glycoprotein Activity In Vitro. J. Pharm. Sci. 2002, 91, 1980-1990.
39. The Pharmacological Effect of Lipids III: Role of Lipids in Cancer Research; Kabara, J. J., Ed.; The American Oil Chemists Society: Phoenix, AZ, 1989.
40. Wang, E.-J.; Casciano, C. N.; Clement, R. P.; Johnson, W. W. Active Transport of Fluorescent P-glycoprotein Substrates: Evaluation as Markers and Interaction with Inhibitors. Biochem. Biophys. Res. Commun. 2001, 289, 580-585.
41. Sharom, F. J.; Liu, R.; Qu, Q.; Romsicki, Y. Exploring the Structure and Function of the P-glycoprotein Multidrug Transporter using Fluorescence Sepctroscopic Tools. Cell Dev. Biol. 2001, 12, 257-266.
42. Doige, C. A.; Yu, X.; Sharom, F. J. The Effects of Lipids and Detergents on ATPase-active P-glycoprotein. Biochim. Biophys. Acta 1993, 1146, 65-72.
43. Ferté, J. Analysis of the Tangled Relationship between P-glycoprotein-mediated Multidrug Resistance and the Lipid Phase of the Cell Membrane. Eur. J. Biochem. 2000, 267, 277-294.
44. Regev, R.; Assaraf, Y. G.; Eytan, G. D. Membrane Fluidization by Ether, Other Anesthetics, and Certain Agents Abolishes P-glycoprotein ATPase Activity and Modulates Efflux from Multidrug-resistant Cells. Eur. J. Biochem. 1999, 259, 18-24.
45. Cornaire, G.; Woodley, J.; Hermann, P.; Cloarec, A.; Arellano, C.; Houin, G. Impact of Excipients on the Absorption of P-glycoprotein Substrates In Vitro and In Vivo. Int. J. Pharm. 2004, 278, 119-131.
46. Shapiro, A. B.; Ling, V. Positively Cooperative Sites for Drug Transport by P-glycoprotein with Distinct Drug Specificities. Eur. J. Biochem. 1997, 250, 130-137.
47. Hirsch-Ernst, K. I.; Ziemann, C.; Rustenbeck, I.; Kahn, G. F. Inhibitors of MDR1-dependent Transport Activity Delay Accumulation of the MDR1 Substrate Rhodamine 123 in Primary Rat Hepatocyte Cultures. Toxicology 2001, 167, 47-57.
48. Litman, T.; Brangi, M.; Hudson, E.; Fetsch, P.; Abati, A.; Ross, D. D.; Miyake, K.; Resau, J. H.; Bates, S. E. The Multidrug-resistant Phenotype Associated with Overexpression of the New ABC Half-transporter, MXR ABCG2). J. Cell. Sci. 2000, 113, 2011-2021.
49. Scotto, K. W. Transcriptional Regulation of ABC Drug Transporters. Oncogene 2003, 22, 7496-7511.
50. Teng, S.; Piquette-Miller, M. Regulation of Transporters by Nuclear Hormone Receptors: Implications during Inflammation. Mol. Pharmaceutics 2008, 5, 67-76.
51. Urquhart, B. L.; Tirona, R. G.; Kim, R. B. Nuclear Receptors and the Regulation of Drug-Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs. J. Clin. Pharmacol. 2007, 47, 566-578.
52. Lee, C. H.; Plutzky, J. Liver X Receptor Activation and High-Density Lipoprotein Biology: A Reversal of Fortune. Circulation 2006, 113, 5-8.
53. Ou, J.; Tu, H.; Shan, B.; Luk, A.; DeBose-Boyd, R. A.; Bashmakov, Y.; Goldstein, J. L.; Brown, M. S. Unsaturated Fatty Acids Inhibit Transcription of the Sterol Regulatory Element-binding Protein-1c (SREBP-1c) Gene by Antagonizing Ligand-dependent Activation of the LXR. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 6027-6032.
54. Yoshikawa, T.; Shimano, H.; Yahagi, N.; Ide, T.; Amemiya-Kudo, M.; Matsuzaka, T.; Nakakuki, M.; Tomita, S.; Okazaki, H.; Tamura, Y.; Iizuka, Y.; Ohashi, K.; Takahashi, A.; Sone, H.; Osuga, J.J.; Gotoda, T.; Ishibashi, S.; Yamada, N. Polyunsaturated Fatty Acids Suppress Sterol Regulatory Element-binding Protein 1c Promoter Activity by Inhibition of Liver X Receptor (LXR) Binding to LXR Response Elements. J. Biol. Chem. 2002, 277, 1705-1711.
55. Chawla, A.; Repa, J. J.; Evans, R. M.; Mangelsdorf, D. J. Nuclear Receptors and Lipid Physiology: Opening the X-files. Science 2001, 294, 1866-1870.
56. Ramjiawan, B.; Czubryt, M. P.; Gilchrist, J. S. C.; Pierce, G. N. Nuclear Membrane Cholesterol Can Modulate Nuclear Nucleoside Triphosphatase Activity. J. Cell. Biochem. 1996, 63, 442-452.
57. Czubryt, M. P.; Russell, J. C.; Sarantopoulos, J.; Pierce, G. N. Nuclear Cholesterol Content and Nucleoside Triphosphatase Activity are Altered in the JCR:LA-cp Corpulent Rat. J. Cell. Biochem. 1996, 63, 349-357.